Please login to the form below

Not currently logged in
Email:
Password:

Libtayo

This page shows the latest Libtayo news and features for those working in and with pharma, biotech and healthcare.

Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients

Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients

In comparison to chemotherapy, Libtayo reduced the risk of death by 31% compared to chemotherapy in the total population. ... The NSCLC authorisation closely followed another approval for Libtayo in previously treated advanced basal cell carcinoma.

Latest news

More from news
Approximately 5 fully matching, plus 19 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics